Mayo Foundation for Medical Education and Research (MFMER) has described glycogen synthase kinase 3 (GSK-3) inhibitors reported to be useful for the treatment of cancer, neurological and psychiatric disorders.
Mayo Foundation for Medical Education and Research (MFMER) and University of Florida have identified atrial natriuretic peptide B (NPR2; guanylate cyclase B) receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of fibrosis.
Scientists at Mayo Foundation for Medical Education and Research (MFMER) and Sanford Burnham Prebys Medical Discovery Institute have described G-protein coupled bile acid receptor 1 (GPBAR1; TGR5; GPCR19; GPR131) antagonists reported to be useful for the treatment of cancer and polycystic liver.
Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of cardiotoxicity.
Researchers at Mayo Foundation for Medical Education and Research (MFMER) and University of Nebraska have described proteolysis targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a hepatocyte growth factor receptor (HGFR; MET)-targeting moiety through a linker reported to be useful for the cancer.
Insitu Biologics Inc. has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for cancer therapeutics.
